Cytomegalovirus immediate-early 1 (IE-1) peptide–HLA class I complex (CMV IE-1–HLA-I complex)

The Cytomegalovirus immediate-early 1 (IE-1) peptide–HLA class I complex is a primary immunological target presented on the surface of cells infected with Human Cytomegalovirus (HCMV). The IE-1 protein, encoded by the UL123 gene, is one of the first viral products synthesized upon infection and is essential for the transactivation of subsequent viral genes and the subversion of host antiviral defenses (Reddehase, 2002, PMID: 12165113). Specific peptides derived from IE-1, most notably the VLEETSVML sequence, are loaded onto HLA class I molecules, such as HLA-A*02:01, for presentation to the immune system (Khan et al., 2002, PMID: 11812997). These complexes are recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes, which are crucial for controlling CMV latency and reactivation. In clinical practice, these complexes are targeted using adoptive T-cell therapies, including TCR-engineered T cells, to restore immunity in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation (Schub et al., 2009, PMID: 19433599). Therapeutic efficacy depends on the stable expression of the HLA molecule and the presence of the specific viral peptide, making HLA typing a prerequisite for treatment (Einsele et al., 2002, PMID: 11781222). Challenges in targeting this complex include the virus's ability to downregulate HLA expression to evade immune detection, though IE-1 remains a dominant target due to its early expression and high conservation.

Other names

HCMV IE1-HLA complexUL123 peptide-MHC complexIE1-derived peptide-HLA-A*02:01 complexCytomegalovirus IE1 antigen-HLA complex

Recognition of the peptide-HLA complex by the T-cell receptor (TCR) of CD8+ T cells, leading to the release of perforin and granzymes and subsequent apoptosis of the infected host cell.